ELMD Electromed, Inc.
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1488917 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.1%
TTM net income YoY45.5%
TTM EPS YoY45.7%
Revenue 3-yr CAGR15.0%
Net income 3-yr CAGR54.4%
Margins
Gross margin79.0%
Operating margin19.5%
Net margin15.8%
FCF margin11.5%
EBITDA margin20.6%
Returns
ROE24.5%
ROA20.8%
ROIC (approx.)34.3%
Asset turnover1.32x
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio7.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio3.6%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $73.78M | $64.00M | $54.72M | $48.07M | $41.66M |
| Cost of revenue | $15.83M | $14.03M | $12.99M | $11.55M | $10.22M |
| Gross profit | $57.94M | $49.97M | $41.73M | $36.52M | $31.44M |
| R&D expense | $1.31M | $996,000 | $656,000 | $916,000 | $1.36M |
| SG&A expense | $42.75M | $39.31M | $34.49M | $31.59M | $27.11M |
| Operating income | $13.88M | $9.66M | $6.58M | $4.01M | $2.97M |
| Pretax income | $14.36M | $10.28M | $7.04M | $4.09M | $3.00M |
| Income tax | $3.06M | $2.75M | $1.89M | $920,000 | $692,000 |
| Net income | $11.30M | $7.54M | $5.15M | $3.17M | $2.31M |
| EBITDA | $14.75M | $10.70M | $7.37M | $4.56M | $3.48M |
| EPS (basic) | 1.37 | 0.89 | 0.60 | 0.37 | 0.27 |
| EPS (diluted) | 1.30 | 0.85 | 0.58 | 0.36 | 0.26 |
| Weighted avg. shares (diluted) | 8.69M | 8.91M | 8.86M | 8.70M | 8.77M |
| Banking | |||||
| Net interest income | — | — | $455,000 | $78,000 | $25,000 |
| Balance sheet | |||||
| Cash & equivalents | $20.45M | $15.29M | $16.08M | $7.37M | $8.15M |
| Receivables | $29.80M | $24.66M | $23.33M | $24.13M | $21.05M |
| Inventory | $3.68M | $3.30M | $3.71M | $4.22M | $3.18M |
| Current assets | $57.37M | $45.08M | $44.17M | $37.79M | $34.54M |
| PP&E, net | $5.21M | $4.71M | $5.17M | $5.67M | $4.57M |
| Intangibles | $379,000 | $371,000 | $657,000 | $605,000 | $599,000 |
| Total assets | $66.27M | $53.80M | $52.23M | $45.81M | $41.36M |
| Current liabilities | $12.22M | $10.47M | $7.68M | $8.05M | $7.15M |
| Total liabilities | $12.29M | $10.59M | $7.69M | $8.14M | $7.19M |
| Shareholders' equity | $53.98M | $43.21M | $44.55M | $37.67M | $34.17M |
| Shares outstanding | 8.37M | 8.35M | 8.64M | 8.56M | 8.48M |
| Cash flow statement | |||||
| Operating cash flow | $9.66M | $11.39M | $9.07M | $1.31M | -$686,000 |
| Capital expenditure | $1.25M | $262,000 | $287,000 | $1.65M | $1.43M |
| Free cash flow | $8.41M | $11.13M | $8.78M | -$333,000 | -$2.11M |
| Investing cash flow | -$1.30M | -$306,000 | -$395,000 | -$1.72M | -$1.52M |
| Financing cash flow | -$3.20M | -$11.88M | $36,000 | -$380,000 | -$1.52M |
| Depreciation & amortization | $868,000 | $1.04M | $789,000 | $550,000 | $503,000 |
| Stock-based compensation | $2.72M | $3.06M | $1.69M | $708,000 | $976,000 |
| Share buybacks | $3.92M | $10.00M | $275,000 | $153,000 | $1.45M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.